241 related articles for article (PubMed ID: 15925224)
21. Pharmacokinetics and hepatic disposition of bis[1-(ethoxycarbonyl)propyl]5-acetylamino-2,4,6-triiodoisophthalate in rats and isolated perfused rat livers.
Liu Y; Bacon ER; Ballinger K; Black CD; Illig K; McIntire GL; Wang PP; O'Neil N; Kinter L; Desai VC
Drug Metab Dispos; 2000 Jul; 28(7):731-6. PubMed ID: 10859144
[TBL] [Abstract][Full Text] [Related]
22. Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics.
Yang Z; Zadjura L; D'Arienzo C; Marino A; Santone K; Klunk L; Greene D; Lin PF; Colonno R; Wang T; Meanwell N; Hansel S
Biopharm Drug Dispos; 2005 Dec; 26(9):387-402. PubMed ID: 16142720
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic analysis of enterohepatic circulation of buprenorphine and its active metabolite, norbuprenorphine, in rats.
Ohtani M; Kotaki H; Uchino K; Sawada Y; Iga T
Drug Metab Dispos; 1994; 22(1):2-7. PubMed ID: 8149883
[TBL] [Abstract][Full Text] [Related]
24. Tissue distribution and biotransformation of zopolrestat, an aldose reductase inhibitor, in rats.
Schneider RP; Fouda HG; Inskeep PB
Drug Metab Dispos; 1998 Nov; 26(11):1149-59. PubMed ID: 9806959
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics and bioavailability of cefquinome in healthy piglets.
Li XB; Wu WX; Su D; Wang ZJ; Jiang HY; Shen JZ
J Vet Pharmacol Ther; 2008 Dec; 31(6):523-7. PubMed ID: 19000274
[TBL] [Abstract][Full Text] [Related]
26. Disposition of amphotericin B in the isolated perfused rat liver.
Hong Y; Ramzan I; McLachlan AJ
J Pharm Pharmacol; 2004 Jan; 56(1):35-41. PubMed ID: 14979999
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate.
Li J; Milne RW; Nation RL; Turnidge JD; Smeaton TC; Coulthard K
J Antimicrob Chemother; 2004 May; 53(5):837-40. PubMed ID: 15044428
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of TDP223206 following intravenous and oral administration to intact rats and intravenous administration to bile duct-cannulated rats.
Chen Y; Cheng D; Marugan JJ; Manthey C; Tomczuk B; Huebert N
Biopharm Drug Dispos; 2008 May; 29(4):219-30. PubMed ID: 18260095
[TBL] [Abstract][Full Text] [Related]
29. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
30. Physiological disposition of aerosolized MK-679 in rats.
Tocco DJ; deluna FA; Vadas E; Lin JH
Drug Metab Dispos; 1992; 20(3):428-31. PubMed ID: 1355719
[TBL] [Abstract][Full Text] [Related]
31. Biliary elimination and hepatic disposition of a new fluoroquinolone, temafloxacin: experimental evaluation.
Brogard JM; Koechlin C; Westphal JF; Blicklé JF; Dorner M; Jehl F
Drugs Exp Clin Res; 1990; 16(8):407-16. PubMed ID: 2097145
[TBL] [Abstract][Full Text] [Related]
32. [Pharmacokinetic properties of rithmidazole upon single intravenous introduction].
Spasov AA; Stepanov AV; Smirnova LA; Petrov VI; Shabasheva IG
Eksp Klin Farmakol; 2002; 65(3):57-61. PubMed ID: 12227100
[TBL] [Abstract][Full Text] [Related]
33. High-performance liquid chromatographic determination and pharmacokinetic study of vitexin-2''-O-rhamnoside in rat plasma after intravenous administration.
Ying X; Gao S; Zhu W; Bi Y; Qin F; Li X; Li F
J Pharm Biomed Anal; 2007 Jul; 44(3):802-6. PubMed ID: 17459645
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of ochratoxin A and its metabolites in rats.
Li S; Marquardt RR; Frohlich AA; Vitti TG; Crow G
Toxicol Appl Pharmacol; 1997 Jul; 145(1):82-90. PubMed ID: 9221827
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of novel antimicrobial cationic peptides NAB 7061 and NAB 739 in rats following intravenous administration.
Ali FE; Cao G; Poudyal A; Vaara T; Nation RL; Vaara M; Li J
J Antimicrob Chemother; 2009 Nov; 64(5):1067-70. PubMed ID: 19744982
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of the sequential metabolites of loteprednol etabonate in rats.
Wu WM; Huang F; Lee Y; Buchwald P; Bodor N
J Pharm Pharmacol; 2008 Mar; 60(3):291-7. PubMed ID: 18284808
[TBL] [Abstract][Full Text] [Related]
37. Formation and elimination of 7-hydroxymethotrexate in the rat in vivo after methotrexate administration.
Bremnes RM; Slørdal L; Wist E; Aarbakke J
Cancer Res; 1989 May; 49(9):2460-4. PubMed ID: 2706634
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics and bioavailability of diisopropanolamine (DIPA) in rats following intravenous or dermal application.
Saghir SA; Frantz SW; Spence MW; Nolan RJ; Lowe ER; Rick DL; Bartels MJ
Food Chem Toxicol; 2007 Oct; 45(10):2047-56. PubMed ID: 17583405
[TBL] [Abstract][Full Text] [Related]
39. Preclinical pharmacology of 2-methoxyantimycin A compounds as novel antitumor agents.
Wang H; Li M; Rhie JK; Hockenbery DM; Covey JM; Zhang R; Hill DL
Cancer Chemother Pharmacol; 2005 Sep; 56(3):291-8. PubMed ID: 15883820
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics and pharmacodynamics of physostigmine in the rat after intravenous administration.
Somani SM; Khalique A
Drug Metab Dispos; 1987; 15(5):627-33. PubMed ID: 2891478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
